Kala Pharmaceuticals Stock News

Kala Pharmaceuticals Inc (KALA) shares closed today at 0.8% above its 52 week low of $1.22, giving the company a market cap of $80M. The stock is currently down 81.9% year-to-date, down 83.9% over the past 12 months, and down 93.3% over the past five years. This week, the Dow Jones Industrial Average rose 1.6%, and the S&P 500 rose 2.3%. Trading Activity Trading volume this week was 18.4% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.0. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 751.6% The company's stock price performance over the past 12 months lags the peer average by 611.6% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

WATERTOWN, Mass., Dec. 17, 2021 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to new employees as inducement awar

Equities analysts expect Kala Pharmaceuticals, Inc. (NASDAQ:KALA) to post sales of $3.49 million for the current fiscal quarter, according to Zacks Investment Research. Six analysts have issued estimates for Kala Pharmaceuticals earnings, with estimates ranging from $3.24 million to $4.01 million. Kala Pharmaceuticals posted sales of $2.24 million in the same quarter last year, which []

California State Teachers Retirement System raised its position in shares of Kala Pharmaceuticals, Inc. (NASDAQ:KALA) by 11.6% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 66,592 shares of the companys stock after acquiring an additional 6,915 shares during the period. California []

Looking for short squeeze penny stocks? Give these 5 a look. The post Best Penny Stocks To Buy Now For A Short Squeeze? 5 To Watch appeared first on Penny Stocks to Buy, Picks, News and Information |

Looking for short squeeze penny stocks? Give these 5 a look.

Nuveen Asset Management LLC trimmed its position in shares of Kala Pharmaceuticals, Inc. (NASDAQ:KALA) by 36.2% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 181,653 shares of the companys stock after selling 102,986 shares during the quarter. Nuveen Asset Management LLC owned []

Cubist Systematic Strategies LLC reduced its position in shares of Kala Pharmaceuticals, Inc. (NASDAQ:KALA) by 65.0% in the second quarter, HoldingsChannel.com reports. The firm owned 44,169 shares of the companys stock after selling 82,085 shares during the period. Cubist Systematic Strategies LLCs holdings in Kala Pharmaceuticals were worth $234,000 at the end of the most []

Wedbush Securities Inc. trimmed its stake in Kala Pharmaceuticals, Inc. (NASDAQ:KALA) by 42.8% during the third quarter, Holdings Channel.com reports. The fund owned 31,376 shares of the companys stock after selling 23,500 shares during the period. Wedbush Securities Inc.s holdings in Kala Pharmaceuticals were worth $82,000 at the end of the most recent quarter. Several []

Zacks Investment Research cut shares of Kala Pharmaceuticals (NASDAQ:KALA) from a hold rating to a sell rating in a research note issued to investors on Thursday morning, Zacks.com reports. According to Zacks, Kala Pharmaceuticals, Inc. is a biopharmaceutical company. It focused on the development and commercialization of therapeutics through its nanoparticle-based Mucus Penetrating Particles technology. []

Kala Pharmaceuticals, Inc. (NASDAQ:KALA) Equities researchers at Wedbush lowered their FY2021 earnings estimates for Kala Pharmaceuticals in a report issued on Tuesday, November 16th. Wedbush analyst L. Moussatos now forecasts that the company will post earnings per share of ($1.87) for the year, down from their prior forecast of ($1.80). Wedbush also issued estimates []

WATERTOWN, Mass., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (Nasdaq:KALA), today announced that the Company granted non-statutory stock options to new employees as inducement awar

Equities analysts forecast that Kala Pharmaceuticals, Inc. (NASDAQ:KALA) will announce earnings of ($0.45) per share for the current quarter, Zacks Investment Research reports. Six analysts have provided estimates for Kala Pharmaceuticals earnings, with the lowest EPS estimate coming in at ($0.47) and the highest estimate coming in at ($0.42). Kala Pharmaceuticals posted earnings of ($0.55) []

Wall Street brokerages expect Kala Pharmaceuticals, Inc. (NASDAQ:KALA) to report earnings of ($0.45) per share for the current fiscal quarter, Zacks reports. Six analysts have issued estimates for Kala Pharmaceuticals earnings, with the lowest EPS estimate coming in at ($0.47) and the highest estimate coming in at ($0.42). Kala Pharmaceuticals posted earnings of ($0.55) per []

Kala Pharmaceuticals (NASDAQ:KALA) had its price target decreased by HC Wainwright from $11.00 to $9.00 in a research note issued to investors on Tuesday, The Fly reports. HC Wainwright currently has a buy rating on the stock. Several other analysts have also recently weighed in on KALA. Zacks Investment Research upgraded shares of Kala Pharmaceuticals []